Increased arterial intima‐media thickness by B‐M mode echodoppler ultrasonography in acromegaly

Colao, Annamaria; Spiezia, Stefano; Cerbone, Gaetana; Pivonello, Rosario; Marzullo, Paolo; Ferone, Diego; Somma, Carolina Di; Assanti, Angelo Pio; Lombardi, Gaetano

doi:10.1046/j.1365-2265.2001.01256.x

Cited by 111 publications

(90 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, there was no evidence for an increased CVD risk or premature CAD in patients with newly diagnosed and treatment-naive acromegaly. This is consistent with an earlier study that demonstrated that the prevalence of atherosclerotic plaques in the common and internal carotid arteries was not higher than in controls (37).…”

Section: Discussionsupporting

confidence: 82%

Acromegaly per se does not increase the risk for coronary artery disease

Akutsu

Kreutzer²,

Wasmeier³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Context: Information about the risk and course of coronary artery disease (CAD) in acromegaly is limited. Objective: To evaluate CAD risk in acromegalic patients at diagnosis and after successful treatment during follow-up. Subjects and methods: Twenty-five consecutive patients (age 45.1G10.6 years, 15 women) were studied at the time of diagnosis, and 19 patients were re-evaluated after 4.6G1.1 years. The European Society of Cardiology (ESC) risk score was calculated, and a cardiac computed tomography was performed for detection and quantification (Agatston score (AS)) of coronary artery calcium (CACs). Fifty age-, sex-, and CAD risk-matched subjects and CAC data from the population-based Heinz Nixdorf Recall (HNR) study served as controls. Results: In 21 of the 25 patients, the 10-year risk of developing CAD according to the ESC risk score was low (!10%) and high (O20%) in four patients. The AS was lower than in controls (2.6G7.9 vs 66G182; PZ0.014) and less patients had a positive CAC (ASO0) (20 vs 48%, PZ0.024), which in the acromegalic patients was less than expected from the HNR study. The AS did not correlate with GH excess or disease duration. In 19 acromegalic patients, who were in remission and re-evaluated after 4.6G1.1 years, the ESC risk (PZ0.102) and the AS (PZ0.173) did not change significantly and no symptomatic CAD event occurred. Conclusion: CAD risk in newly diagnosed acromegalic patients was low and remained stable after successful treatment. CAC was lower than in controls suggesting that GH excess per se does not carry an additional CAD risk.

show abstract

Section: Discussionsupporting

confidence: 82%

Acromegaly per se does not increase the risk for coronary artery disease

Akutsu

Kreutzer²,

Wasmeier³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In this respect, it is worth noting that while almost one-half of acromegalic patients of this series presented cardiac anomalies, only three of them had documented coronary artery disease. Moreover, previous studies reported that in acromegalic patients well-defined carotid wall plaques were as frequent as in healthy subjects (36), consistent with the view that atherosclerotic vascular damage does not represent the main determinant of elevated cardiovascular mortality in acromegaly (23).…”

Section: Discussionsupporting

confidence: 68%

Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients

Ronchi

Corbetta

Cappiello

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Adiponectin (ApN) is an adipocytokine expressed in human adipose cells with anti-atherogenic and anti-inflammatory properties that plays a role in the pathophysiology of insulin resistance, metabolic syndrome and coronary artery disease. The aim of the study was to evaluate ApN secretion in patients with acromegaly, a chronic disease associated with insulin resistance and increased cardiovascular mortality, and to correlate ApN levels with hormonal, metabolic and cardiovascular parameters. Design and methods: The study included 32 patients with active acromegaly (11 male and 21 female, aged 48^11 years, duration of disease: 8^6 years, GH: 9.2^9.8 mg/l, IGF-I: 80^33 nmol/l (meansŜ .D.)) and 38 control subjects sex-and body mass index (BMI)-matched. In all subjects, serum ApN, leptin and ghrelin levels, BMI, waist circumference, insulin resistance (assessed by homeostasis model assessment and the quantitative insulin check index), lipid profile and blood pressure values were evaluated. Results: Acromegalic patients and control subjects had similar ApN levels (9.4^3.5 vs 9.5^4.0 mg/l, NS), while when considering obese subjects acromegalic patients had ApN levels significantly higher than controls (10.2^4 vs 7.5^3 mg/l, P , 0.05). No significant correlation between ApN and GH/IGF-I levels or duration of disease was found. ApN concentrations negatively correlated with BMI, waist circumference, glucose and diastolic blood pressure and positively with high-density lipoprotein cholesterol and ghrelin in controls, while all these correlations were lost in acromegalic patients. Conclusions: We provide evidence that, although metabolic and cardiovascular abnormalities are present in most acromegalic patients, in these subjects ApN levels are not reduced and, contrary to what is found in BMI-matched controls, do not correlate with cardiovascular risk factors. These data support the view that atherosclerosis is not the main determinant of cardiovascular mortality in acromegaly and suggest a permissive action of GH and/or IGF-I excess on ApN secretion.

show abstract

“…These data suggest a beneficial effect of IGF-I on the vasculature. In contrast, the correction of growth hormone overproduction in acromegalic patients also resulted in reversion of IMT thickening (37). Therefore, the influence of the IGF-system on atherosclerosis is complex and may be substantially modulated by the metabolic state.…”

Section: Linear Regression Analysesmentioning

confidence: 89%

Reduced IGFBP-1 Is Associated With Thickening of the Carotid Wall in Type 2 Diabetes

Leinonen

Salonen

et al. 2002

Diabetes Care

View full text Add to dashboard Cite

OBJECTIVE -The aim of the present study was to assess the role of the insulin-like growth factor (IGF) system and lipids in predicting the carotid intima-media thickness (IMT) in type 2 diabetes. RESULTS -Partial correlations adjusted for age, sex, BMI, and diabetes duration showed an inverse association of IGFBP-1 with C-peptide (r ϭ Ϫ0. 24, P ϭ 0.018) and with maximal IMT (r ϭ Ϫ0.42, P Ͻ 0.001), whereas IGF I and IGFBP-3 correlated positively with several riskpromoting lipid parameters. In linear regression analysis controlling for age, sex, BMI, diabetes duration, and presence or absence of oral antihyperglycemic or insulin medication, determinants of IMT were age, IGFBP-1, pulse pressure, Lp(a), diabetes duration, and insulin treatment. IGFBP-1 persisted in the model for subjects with CVD. RESEARCH DESIGN AND METHODSCONCLUSIONS -In summary, a decrease in IGFBP-1 is a marker of carotid IMT thickening in patients with type 2 diabetes.

show abstract

Increased arterial intima‐media thickness by B‐M mode echodoppler ultrasonography in acromegaly

Cited by 111 publications

References 59 publications

Acromegaly per se does not increase the risk for coronary artery disease

Acromegaly per se does not increase the risk for coronary artery disease

Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients

Reduced IGFBP-1 Is Associated With Thickening of the Carotid Wall in Type 2 Diabetes

Contact Info

Product

Resources

About